Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce it has signed an exclusive distribution agreement with Al Zahrawi Medical Supplies LLC, a premier medical device distributor based in Dubai, United Arab Emirates. The agreement grants Al Zahrawi Medical Supplies exclusive rights to market and distribute OncoSil™ across the Gulf Cooperation Council (GCC) countries, which include the United Arab Emirates (UAE), Qatar, Oman, and Bahrain.
Further expansion with a proven quality distributor. This could assist to revenue going forward as Oncosil has previously mentioned, revenue is looking better regardless.
OSL Price at posting:
1.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)